- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02545062
MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes
Early Detection of Mild Cognitive Impairment in Young Diabetes Patients Using the MoCa Test
T2D and cognitive impairment are two of the most common chronic condition found in persons 60 years and older. Diabetes type 2 increases with age and studies suggest that the diabetes is one of the risk factor for cognitive impairment and dementia.
Although there is much recent research showing that diabetics at every age have more cognitive impairment and dementia than non-diabetics, relatively little attention has been paid to the implications of this complication in the management of T2D in terms of screening, prevention, education and treatment adherence.
There are now guidelines for periodic evaluation of patients with diabetes as early detection of complications of the disease, but so far there are no similar assessment and monitoring of cognitive function.
In this study the investigators examine cognitive function in young diabetic patients (from 20 to 55) using the MoCa test, that allows detection of mild cognitive impairment, and may be carried out during a visit, an annual advisory diabetes clinic.
Study Overview
Status
Intervention / Treatment
Detailed Description
- Patients on a routine visit to the diabetes clinic, who meet the inclusion criteria, will be recruited for the test. They will be given an explanation of the study and the questionnaire by the principal investigator.
- Sign a consent form.
Performance and execution of MOCA test:
- Fingerstick blood glucose for pre-cognitive testing performed (to avoid testing any participant with a serum glucose < 70 mg/dl);
- In the presence of hypoglycemia, the participant should be given a snack and begin the test only after the glucose level rises. Alternatively delay executing the Test
- Details from the patient's file are registered, such as: duration of the disease, family history, presence of macro and micro vascular complications, lifestyle, years of education, and the results of relevant laboratory accuracy.
- For each patient a medical file is opened containing the initials and serial number of his research. All results are then encoded and analyzed anonymously
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nes Tziona, Israel, 7404964
- Recruiting
- Viviana Ostrovsky
-
Contact:
- Viviana VO Ostrovsky, MD
- Phone Number: +972503265303
- Email: vivianaos@clalit.org.il
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- type 1 and 2 diabetes meIlitus
- 20 to 55 years old
- up to 15 years of diabetes disease duration
- fluent speech and read hebrew's language only
Exclusion Criteria:
- not meeting the inclusion criteria
- psychiatric disease
- dementia
- chronic use of alcohol or illegal drugs
- use of medication that can alter the attention or cognition of the participant
- active cardiovascular disease in the previous six months before the investigation
- oncology disease in the previous six months before the investigation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: group of type 1 and 2 diabetics
A group of type 1 and 2 diabetes patients who meets the inclusion criteria will be done the MoCa test. A fingertip blood glucose will be made previous to the begin with the test in order to avoid doing it on a hypoglycemia event. The participants are instructed to do or respond the items in a organized manner. For each items there's a score. If the participant has 12 years of education or fewer, a point is added to his total score. At the end of the test the investigator will sum all sub items scores listed on the right side of the test paper. The maximum score is 30. The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria. |
The MoCa test is actually used for the screening of Mild Cognitive Impairment .
It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic.
The MoCa assesses several cognitive domains, and it is available in hebrew language.
|
Experimental: control group
The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria.
|
The MoCa test is actually used for the screening of Mild Cognitive Impairment .
It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic.
The MoCa assesses several cognitive domains, and it is available in hebrew language.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The differences between the MoCa test score in diabetics and in a control group of non diabetics
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The relation between the MoCa test score and glycemic control, in terms of HA1C value, in the past year before recruitment
Time Frame: 1 year
|
1 year
|
The relation between the MoCa test score and the presence of microvascular complications, retinopathy, polyneuropathy and nephropathy
Time Frame: 1 year
|
1 year
|
The relation between the MoCa test score and the presence of macrovascular complication, ischemic heart disease, non-fatal myocardial infarct, stable and unstable angina, heart failure, non-fatal stroke, peripheral vascular disease
Time Frame: 1year
|
1year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Joel JS Singer, MD, Clalit Medical Service
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DM- MOCA- 1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on MoCa test
-
Dr Abdurrahman Yurtaslan Ankara Oncology Training...CompletedPostoperative Cognitive Dysfunction | Preoperative AnxietyTurkey
-
Rambam Health Care CampusRecruitingCognitive DysfunctionIsrael
-
Aydin Adnan Menderes UniversityRecruitingPostoperative DeliriumTurkey
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingGlioma | Healthy | Breast Cancer | GlioblastomaFrance
-
University Medical Centre MariborRecruitingCardiac Disease | Cardiac Valve DiseaseSlovenia
-
Goztepe Training and Research HospitalTerminatedCognitive Impairment | Type2 DiabetesTurkey
-
Massachusetts General HospitalEnrolling by invitation
-
Andreas MonschCompletedCognitive Impairment | Dementia | Cognitive Change | Cognition Disorders | Cognitive Decline | Dementia, Alzheimer Type | Cognitive Deterioration | Cognitive Symptom | Cognition Disorders in Old Age | Dementia Alzheimers | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Dementia, Mild | Cognitive Abnormality
-
University of FloridaCompletedPostoperative Delirium | Postoperative Cognitive DysfunctionUnited States
-
Mansoura University HospitalCompleted